spacer
home > pmps > winter 2001 > child-resistant clinical trials packaging
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Child-Resistant Clinical Trials Packaging

Many pharmaceutical companies operating on a global basis are worried by the Consumer Product and Safety Commission's (CPSC) enforcement (which began on 23rd November 2000) of child-resistant packaging for clinical trials packs containing a potentially hazardous amount of drug, as part of America's Poison Prevention Packaging Act (PPPA). This could have a knock-on effect for the packaging of clinical trials in Europe with the recent introduction of the EU GCP Clinical Trials Directive, signed in December 2000 and to be implemented into member states legislation within two years.

Consumer groups in Europe are campaigning for standards for child resistance compliance to be brought more in line with the US protocol.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Colin Scaife, Managing Partner of C.E. Packaging Partnership
Colin Scaife formed C.E. Packaging Partnership to provide small and medium-sized pharmaceutical and health care companies with independent access to packaging development expertise and help in their understanding of legislation. He has over 30 years' experience of the packaging of pharmaceutical, health care and FMCGH products and is keen to promote innovative and practical packaging. He is Chairman of the joint ABPI/PAGB technical working party, monitoring packaging issues on behalf of the industry. He is also a recognised expert in the field of child-resistant packaging, being the Convenor of both the European and international standards committees, through which he drafts standards for the testing of child-resistant packaging.

spacer
Colin Scaife
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Irelandís premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement